Philip Morris International is in focus after the U.S. Food and Drug Administration authorized its ZYN nicotine pouches as modified risk tobacco products, a first for the category. The stock has rallied 22.3% over the past 90 days and 147.74% over five years, pushing it near the average analyst price target. A widely followed narrative pegs fair value at $193.14, implying about 10% upside from the last close of $192.98, driven by strong growth in smoke-free platforms like IQOS, ZYN, and VEEV. However, the company's price-to-earnings ratio of 27.2 times exceeds its estimated fair ratio of 25.4 times and the peer average of 22 times, suggesting much optimism is already priced in. Investors must weigh the risk that declining cigarette volumes or a slowdown in the smoke-free rollout could pressure revenue and margins.
Philip Morris International IncFDA authorized ZYN nicotine pouches as modified risk tobacco products, a first for the category.